With news of Axovant’s big failure in Alzheimer’s, the drug industry is looking ahead to its next major crack at the disease — and it’s a long wait.
In 2019, three large, late-stage Alzheimer’s trials are expected to read out, providing what could be the final word on a trio of drugs that scientists and analysts say represent the next best hope of breaking the industry’s generation of failure in the field.
About the Author Reprints
